• Order to parcel locker

    Order to parcel locker
  • easy pay

    easy pay
  • Reduced price
Alzheimer's Disease Drug Development: Research and Development Ecosystem

Alzheimer's Disease Drug Development: Research and Development Ecosystem

9781108838665
598.44 zł
538.59 zł Save 59.85 zł Tax included
Lowest price within 30 days before promotion: 538.59 zł
Quantity
Available in 4-6 weeks

  Delivery policy

Choose Paczkomat Inpost, Orlen Paczka, DPD or Poczta Polska. Click for more details

  Security policy

Pay with a quick bank transfer, payment card or cash on delivery. Click for more details

  Return policy

If you are a consumer, you can return the goods within 14 days. Click for more details

Description
Alzheimers Disease (AD) is a growing global public health challenge. The development of new therapies is urgently needed, and a complex ecosystem of organizations has grown to facilitate AD drug discovery and development. Masterfully collating information on the drug development ecosystem, this book emphasizes the contributions of each aspect in the pipeline with a uniform approach to chapters, enabling readers to access relevant information quickly. Topics covered include the use of non-clinical laboratory studies, biomarker development, artificial intelligence, design and management of clinical trials, and funding and financing models. Also discussed is the critical role of advocacy fundraising for drug development. With the approval of aducanumab, the function of the ecosystem has become apparent. This is a definitive overview of how the ecosystem works in transferring an AD drug from its discovery in the laboratory through clinical trial testing to regulatory review and eventual marketing.
Product Details
92931
9781108838665
9781108838665

Data sheet

Publication date
2022
Issue number
1
Cover
hard cover
Pages count
574
Dimensions (mm)
183.00 x 259.00
Weight (g)
1340
  • Part I. Advancing Alzheimer therapies in a collaborative science ecosystem; Part II. Non-Clinical assessment of Alzheimer candidate drugs; Part III. Alzheimer clinical trials; Part IV. Imaging and biomarker development in Alzheimer drug discovery; Part V. Academic drug development programs; Part VI. Public-Private partnerships in Alzheimer drug development; Part VII. Funding and financing Alzheimer drug development.
Comments (0)